

Katten

615 S. College Street
Suite 1700
Charlotte, NC 28202-3354
+1.704.444.2000 tel
katten.com

JOE JANUSZ
joe.janusz@katten.com
+1.704.344.3182 direct
+1.704.444.2050 fax

January 6, 2026

Anish Bhatnagar, MD – Chairman and CEO
Jesse Schumaker – General Counsel
Solenio Therapeutics, Inc.
100 Marine Parkway
Suite 400
Redwood City, CA 94065

Re: CREATES Act Request – VYKAT XR®

Dear Dr. Bhatnagar and Mr. Schumaker:

Pursuant to § 610 of the Further Consolidated Appropriations Act of 2020, Pub. L. No. 116-94 (the “CREATES Act”), I write on behalf of Apotex Inc. (“Apotex”) to request that, within 14 days after the date on which Soleno Therapeutics, Inc. receives this written request, you exercise your authority as a named corporate officer of Soleno Therapeutics, Inc. to ensure the offer of the following quantities of VYKAT XR® (the “Product”) to Apotex at the address listed below:

Product	Description	NDC	Quantity
VYKAT XR® 150mg	Diazoxide choline extended-release tablets, 150 mg	83860-0150-01	1 – 30 tablet container

Delivery Address:

ATTN: Babu Nair
Apotex Inc.
150 Signet Drive
Toronto ON M9L1T9
Canada

By way of background, Apotex seeks to perform development activities pursuant to an application for approval under subsection (b)(2) or (j) of Section 505 of the Federal Food, Drug, and Cosmetic Act (“FDCA”) that relies on the Product as the reference listed drug. *See* CREATES Act § 610(a)(4). In accordance with § 610(a)(10) of the CREATES Act, Apotex has determined that the requested quantities of product would allow it to conduct testing to support an application under (b)(2) or (j) of section 505 of the FDCA and to fulfill regulatory requirements relating to the

January 6, 2026

Page 2

approval of such an application. We will let you know if, in the future, Apotex determines that additional product quantities are needed to support these activities.

Consistent with §§ 610(a)(1) and 610(b)(2)(ii) of the CREATES Act, Apotex hereby agrees to acquire the Product at commercially reasonable, market based terms, i.e., a nondiscriminatory price for the sale of the covered product at or below, but not greater than, the most recent wholesale acquisition cost for the requested product samples, as defined in section 1847A(c)(6)(B) of the Social Security Act. At your earliest opportunity and being mindful that the CREATES Act requires you to complete the transfer of the requested samples to Apotex within 31 days of the date Soleno Therapeutics, Inc. receives this letter, *see* CREATES Act § 610(a)(1)(B) (cross-referencing *id.* § 610(b)(2)(A)(iv)), please send Apotex an invoice that (1) reflects the total cost for the requested samples, and (2) provides standard payment instructions so that the sale and transfer of the requested samples may be completed without undue delay. Accordingly, Apotex expects an offer within 14 days, and delivery of such product within 31 days of Soleno Therapeutics, Inc.'s receipt of this letter.

In accordance with § 610(b)(2)(A)(iii) of the CREATES Act, please direct both the invoice and any questions to:

Reena Vaya

Apotex Inc.

150 Signet Drive

Toronto ON M9L1T9

Canada

rvaya@apotex.com

Thank you for your prompt attention to this matter.

Sincerely,



Joe Janusz